Table 4.
Baseline characteristics of the four groups categorized as low or high HDL-C levels at week 0 in the placebo and policosanol groups.
| Placebo | Policosanol | |||
|---|---|---|---|---|
| Low (n = 8) | High (n = 9) | Low (n = 8) | High (n = 7) | |
| HDL-cholesterol, mg/dL | 57.6 ± 5.5 | 73.7 ± 5.9† § | 56.0 ± 6.3 | 72.6 ± 9.3* § |
| HDL efflux capacity, % | 15.0 ± 0.6 | 15.9 ± 0.5 | 15.3 ± 0.5 | 16.7 ± 1.0† ‡ |
| Total cholesterol, mg/dL | 210.3 ± 15.2 | 218.9 ± 16.3 | 213.3 ± 16.4 | 224.4 ± 9.8 |
| LDL-cholesterol, mg/dL | 137.1 ± 8.5 | 131.6 ± 12.9 | 136.8 ± 13.5 | 124.1 ± 10.4 |
| Triglycerides, mg/dLa | 118.0 [69.8–136.0] | 58.0 [53.0–82.0] | 122.5 [81.3–188.8] | 50.0 [50.0–109.0] |
| Apolipoprotein AI, mg/dL | 160.0 ± 17.6 | 178.9 ± 13.2 | 169.3 ± 16.7 | 196.3 ± 18.0† ‡ |
| Apolipoprotein AII, mg/dL | 32.7 ± 4.3 | 36.0 ± 4.4 | 34.8 ± 3.4 | 34.1 ± 2.7 |
| Apolipoprotein B100, mg/dL | 78.3 ± 19.8 | 79.0 ± 29.0 | 86.0 ± 18.6 | 81.7 ± 12.2 |
| Apolipoprotein B48, mg/dLa | 0.28 [0.22–1.02] | 0.43 [0.26–0.9] | 0.26 [0.17–0.79] | 0.35 [0.19–0.55] |
Values represent the mean ± standard deviation or median with interquartile range.
a
Triglyceride and apolipoprotein B-48 in both groups were log-transformed prior to analysis. *p < 0.05; †p < 0.01 vs. placebo low HDL-C group, ‡p < 0.05; §p < 0.01 vs. policosanol low HDL-C group.